KZIA

Kazia Therapeutics Ltd Sponsored ADR (KZIA) | Rumor.io

Kazia Therapeutics

KZIA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,426

Bullish sentiment (50-day avg)82%

Price to earnings ratio-0.51

Market capitalization149.3M

Earnings per share-7.45

Dividend yield (TTM)—

Revenue (annual)42K

Net income (annual)-20.7M

Social

What share of all stock conversation is about KZIA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Sep 1

Kazia Therapeutics Limited has expanded its clinical trial into HR+/HER2- breast cancer, supported by preclinical data showing strong clinical activity and safety.
The company has received positive comments from research firms, including a Buy rating from BTIG and a $29 target price from Canaccord.
Kazia Therapeutics has secured $40M upfront from an oversubscribed offering, with warrants lifting total potential gross proceeds to $120M.

Generated by AI

Sentiment

Of the messages about KZIA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	76.47% -23.53	85.71% +5.71	87.23% +2.42
Bearish	0%	23.53% +23.53	14.29% -5.71	12.77% -2.42

Bullish· Aug 27

The company has shown promising results in Stage 4, triple-negative breast cancer trials, with a 100% clinical benefit and significant tumor reduction in some cases.
Kazia Therapeutics is actively expanding its trials and research, with new trials in progress for HR+/HER-, early-stage TNBC and CRC, indicating potential for significant growth and opportunities.
The company's initial public offering (IPO) is expected to provide cash for expansion trials and potentially fend off large shareholders at current pricing, suggesting a positive structure for the company's future.

Bearish· Aug 27

The company's stock price may drop further after a public offering, as indicated by the phrase "what happened to $50mil offerings they did".
Kazia Therapeutics Limited's stock price has been affected by a lack of transparency, with one post suggesting the company "did not release a dilution news after PR".
The company's management has been criticized for their handling of the stock, with one post stating "what a horrible way to treat your shareholders" and another calling them "cockroaches".

Generated by AI

Topics

Of the messages about KZIA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	66.67%	77.88%	59.8%
Analysts	—	33.33%	11.54%	14.29%
Macro	—	0%	10.58%	13.66%
Controversies	—	0%	0%	0.23%
Earnings	—	0%	0%	0.16%
Technical Analysis	—	0%	0%	11.87%

Announcements· Nov 19

Kazia Therapeutics Limited (KZIA) reported an initial immune-complete response in a stage IV triple-negative breast cancer patient treated under an FDA-authorized expanded access protocol.
The company announced acceptance of two presentations at the 2025 San Antonio Breast Cancer Symposium, scheduled Dec. 10-14.
Kazia Therapeutics reported an initial immune-complete response in metastatic TNBC and outlined its Q4 oncology pipeline, including a new PD-L1 degrader program expanding the oncology pipeline.

Technical Analysis· Nov 19

$KZIA has a strong resistance at $8.20 and a potential break above $8.40 could lead to short covering.
The stock has a bullish setup with a potential break over highs and strong higher lows, with a price target of $10 to $12.00+.
$KZIA has a descending wedge pattern and is trying to curl off it, with a need to break the VWAP to continue the upward momentum.

Generated by AI

Community

Of the messages about KZIA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	84.62%	81.53%	56.34%
Newcomers	0%	15.38%	18.47%	43.66%

Regulars· Sep 1

The regulars are focused on Kazia Therapeutics' (KZIA) dilutive warrants, which have resulted in a 200% overhang, and the company's poor management under new CFO Levine, with the stock potentially running for an ATM tap in the mid 20's if not for this mistake.
Kazia Therapeutics' (KZIA) recent milestones, including the expansion of their clinical trial into HR+/HER2- breast cancer, have been met with excitement, with the company having a clear plan to continue without a major Big Pharma acquisition.
Kazia Therapeutics' (KZIA) new indications and potential multi-billion dollar revenue streams have been highlighted, with the company's current market cap under $300M and the potential for $140M in cash if warrants are exercised, making them fully funded and poised for success.

Newcomers· Aug 27

The company has reported a 100% clinical benefit rate in initial six patients treated for advanced triple-negative breast cancer, with durable complete metabolic response ongoing since November 2025.
The company has announced excellent initial results for TNBC, with opportunities for expansion trials and potential to fend off a large shareholder at current pricing.
The company is planning an offering with a very low price, which may provide cash for expansion trials and could lead to a strong revaluation of the company's market cap.

Generated by AI

News

Kazia receives $2m milestone as paxalisib epilepsy trial starts

7d agoInvesting.com

Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq

Detailed price information for Kazia Therapeutics Ltd ADR (KZIA-Q) from The Globe and Mail including charting and trades.

10d agoThe Globe and Mail

Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer - Slideshow (NASDAQ:KZIA) 2026-09-11

18d agoSeeking Alpha

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that the first patient has been dosed in Arm A of PNOC035, a Phase 2 platform study evaluating paxalisib in combination with gemcitabine for patients ages 1 to 39 with recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT). AT/RT is w

21d agoYahoo Finance

Kazia (KZIA) Raises Approximately $40M in Gross Proceeds and Expands Paxalisib. Is the Capital Base Stronger than the Clinical Evidence?

Kazia Therapeutics Limited (NASDAQ:KZIA) has materially strengthened its financing position, but the clinical case for expanding paxalisib into HR-positive, HER2-negative metastatic breast cancer remains at the preclinical stage. Paxalisib is an investigational, brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway. On August 31, Kazia Therapeutics Limited (NASDAQ:KZIA) closed a registered public offering that Kazia Therapeutics Limited (NASDAQ:KZIA) […]

21d agoYahoo Finance

Exclusive BAC Article: Kazia Therapeutics; Positive Phase 1 TNBC Data, Interim Combination Data 2026/2027, HR+/HER2- BC Expansion, And Catalysts (NASDAQ:KZIA)

28d agoSeeking Alpha

Also Discussed

Investors talking about KZIA also mention

#	Name	Attention
1	Autonomix Medical Inc.AMIX	0%0
2	ZAPP - Zapp Electric Vehicles Group Limited	——
3	Locafy LimitedLCFY	0%new
4	PeakShares Sector Rotation ETFPSTR	0%new
5	TMT Acquisition CorpTMTC	0%0
6	RNLX - Renalytix Plc	——
7	Cetus Capital Acquisition Corp. - Class A Common StockCETU	0%0
8	Bowen Acquisition Corp.BOWN	0%0
9	AKYA - Akoya Biosciences, Inc.	——
10	Westrock Coffee Co.WEST	0%0

Kazia Therapeutics Ltd Sponsored ADR

Healthcare
Biotechnology

Kazia Therapeutics Ltd Sponsored ADR is a clinical-stage biotechnology company focused on oncology drug development. The company’s current programs center on investigational cancer therapies, including paxalisib, a brain-penetrant small-molecule candidate being developed for hard-to-treat brain tumors, and EVT801, a selective inhibitor targeting pathways involved in tumor growth and angiogenesis. Kazia Therapeutics also advances other research-stage assets aimed at addressing unmet needs in cancer treatment. Its work spans pharmaceutical discovery, preclinical research, and clinical development, with a particular emphasis on brain cancer and other aggressive solid tumors. As an ADR structure, it provides U.S. market access to an Australian-based biotechnology company whose business is concentrated on experimental therapeutics rather than commercialized products.

Website

Location

Three International Towers

Sydney, NSW, 2000

Australia

Social

What share of all stock conversation is about KZIA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Sep 1

Kazia Therapeutics Limited has expanded its clinical trial into HR+/HER2- breast cancer, supported by preclinical data showing strong clinical activity and safety.
The company has received positive comments from research firms, including a Buy rating from BTIG and a $29 target price from Canaccord.
Kazia Therapeutics has secured $40M upfront from an oversubscribed offering, with warrants lifting total potential gross proceeds to $120M.

Generated by AI

Sentiment

Of the messages about KZIA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	76.47% -23.53	85.71% +5.71	87.23% +2.42
Bearish	0%	23.53% +23.53	14.29% -5.71	12.77% -2.42

Bullish· Aug 27

The company has shown promising results in Stage 4, triple-negative breast cancer trials, with a 100% clinical benefit and significant tumor reduction in some cases.
Kazia Therapeutics is actively expanding its trials and research, with new trials in progress for HR+/HER-, early-stage TNBC and CRC, indicating potential for significant growth and opportunities.
The company's initial public offering (IPO) is expected to provide cash for expansion trials and potentially fend off large shareholders at current pricing, suggesting a positive structure for the company's future.

Bearish· Aug 27

The company's stock price may drop further after a public offering, as indicated by the phrase "what happened to $50mil offerings they did".
Kazia Therapeutics Limited's stock price has been affected by a lack of transparency, with one post suggesting the company "did not release a dilution news after PR".
The company's management has been criticized for their handling of the stock, with one post stating "what a horrible way to treat your shareholders" and another calling them "cockroaches".

Generated by AI

Topics

Of the messages about KZIA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	66.67%	77.88%	59.8%
Analysts	—	33.33%	11.54%	14.29%
Macro	—	0%	10.58%	13.66%
Controversies	—	0%	0%	0.23%
Earnings	—	0%	0%	0.16%
Technical Analysis	—	0%	0%	11.87%

Announcements· Nov 19

Kazia Therapeutics Limited (KZIA) reported an initial immune-complete response in a stage IV triple-negative breast cancer patient treated under an FDA-authorized expanded access protocol.
The company announced acceptance of two presentations at the 2025 San Antonio Breast Cancer Symposium, scheduled Dec. 10-14.
Kazia Therapeutics reported an initial immune-complete response in metastatic TNBC and outlined its Q4 oncology pipeline, including a new PD-L1 degrader program expanding the oncology pipeline.

Technical Analysis· Nov 19

$KZIA has a strong resistance at $8.20 and a potential break above $8.40 could lead to short covering.
The stock has a bullish setup with a potential break over highs and strong higher lows, with a price target of $10 to $12.00+.
$KZIA has a descending wedge pattern and is trying to curl off it, with a need to break the VWAP to continue the upward momentum.

Generated by AI

Community

Of the messages about KZIA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	84.62%	81.53%	56.34%
Newcomers	0%	15.38%	18.47%	43.66%

Regulars· Sep 1

The regulars are focused on Kazia Therapeutics' (KZIA) dilutive warrants, which have resulted in a 200% overhang, and the company's poor management under new CFO Levine, with the stock potentially running for an ATM tap in the mid 20's if not for this mistake.
Kazia Therapeutics' (KZIA) recent milestones, including the expansion of their clinical trial into HR+/HER2- breast cancer, have been met with excitement, with the company having a clear plan to continue without a major Big Pharma acquisition.
Kazia Therapeutics' (KZIA) new indications and potential multi-billion dollar revenue streams have been highlighted, with the company's current market cap under $300M and the potential for $140M in cash if warrants are exercised, making them fully funded and poised for success.

Newcomers· Aug 27

The company has reported a 100% clinical benefit rate in initial six patients treated for advanced triple-negative breast cancer, with durable complete metabolic response ongoing since November 2025.
The company has announced excellent initial results for TNBC, with opportunities for expansion trials and potential to fend off a large shareholder at current pricing.
The company is planning an offering with a very low price, which may provide cash for expansion trials and could lead to a strong revaluation of the company's market cap.

Generated by AI

Kazia Therapeutics

Social

Sep 1

Bullish· Aug 27

Bearish· Aug 27

Announcements· Nov 19

Technical Analysis· Nov 19

Regulars· Sep 1

Newcomers· Aug 27

Kazia receives $2m milestone as paxalisib epilepsy trial starts

Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq

Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer - Slideshow (NASDAQ:KZIA) 2026-09-11

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Kazia (KZIA) Raises Approximately $40M in Gross Proceeds and Expands Paxalisib. Is the Capital Base Stronger than the Clinical Evidence?

Exclusive BAC Article: Kazia Therapeutics; Positive Phase 1 TNBC Data, Interim Combination Data 2026/2027, HR+/HER2- BC Expansion, And Catalysts (NASDAQ:KZIA)

Also Discussed

Kazia Therapeutics Ltd Sponsored ADR

Company Information

Location

Kazia receives $2m milestone as paxalisib epilepsy trial starts

Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq

Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer - Slideshow (NASDAQ:KZIA) 2026-09-11

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Kazia (KZIA) Raises Approximately $40M in Gross Proceeds and Expands Paxalisib. Is the Capital Base Stronger than the Clinical Evidence?

Exclusive BAC Article: Kazia Therapeutics; Positive Phase 1 TNBC Data, Interim Combination Data 2026/2027, HR+/HER2- BC Expansion, And Catalysts (NASDAQ:KZIA)

Also Discussed

Social

Sep 1

Bullish· Aug 27

Bearish· Aug 27

Announcements· Nov 19

Technical Analysis· Nov 19

Regulars· Sep 1

Newcomers· Aug 27